In vitro drug interactions of gallates with antibiotics in Staphylococcus Aureus

The antimicrobial activities of tetracycline, mupirocin, and fusidic acid are tested in combination with Epicatechin Gallate (ECG), and Ethyl Gallate (EG) using 2 Methicillin resistant (MRSA) and 2 Methicillin sensitive (MSSA) strains of Staphylococcus aureus. Sub-inhibitory concentration of EG at 2...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioscience (Elite edition) Vol. 2; no. 2; p. 668
Main Authors Soe, Win Mar, Tzer Pin Lin, Raymond, Chu Sing Lim, Lim, Sakharkar, Kishore R, Sakharkar, Meena K
Format Journal Article
LanguageEnglish
Published Singapore 01.01.2010
Subjects
Anti-Bacterial Agents - pharmacology
Catechin - analogs & derivatives
Catechin - pharmacology
Drug Interactions - physiology
Fusidic Acid
Gallic Acid - analogs & derivatives
Gallic Acid - pharmacology
In Vitro Techniques
Methicillin-Resistant Staphylococcus aureus - drug effects
Methicillin-Resistant Staphylococcus aureus - metabolism
Microbial Sensitivity Tests
Mupirocin
Tetracycline
Online AccessGet more information

Cover

More Information
Summary:The antimicrobial activities of tetracycline, mupirocin, and fusidic acid are tested in combination with Epicatechin Gallate (ECG), and Ethyl Gallate (EG) using 2 Methicillin resistant (MRSA) and 2 Methicillin sensitive (MSSA) strains of Staphylococcus aureus. Sub-inhibitory concentration of EG at 256 mg l-1 is found to be synergistic when used in combination with tetracycline, mupirocin, and fusidic acid; and a sub-inhibitory concentration of ECG at 32 mg l-1 is found to be synergistic with tetracycline in all the four Staphylococcus aureus strains tested. The synergistic combinations reduce the MICs of all the above three antibiotics by 4 fold. Combining ECG at 32 mg l-1 with mupirocin, reduces the MIC of mupirocin by four fold in MSSA C1 strain. 74 per cent of the combinations show consistent results in both time-kill assay and checkerboard method. The identified combinations may lead towards novel therapeutic interventions for treating MRSA infections.
ISSN:1945-0508